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Summary/Comment: The single-nucleotide polymorphism (SNP) at rs12979860, formerly known as IL28B, resides within the interferon lambda 4 (IFNL4) gene and is known to favourably influence response to pegylated interferon (PEG IFN)/ribavirin treatment for chronic HCV infection. This study addressed the possible impact of IFNL4 status on naturally occurring HCV resistance-associated variants (RAVs) in a large European cohort and how any associations between IFNL4 and RAVs may impact response to direct-acting antiviral therapy. The findings are important in demonstrating that the non-structural 5A (NS5A) RAV, Y93H, occurs not infrequently in genotype 1b-infected patients (14%) and is significantly associated with the "favourable" IFNL4 status, observations that may explain a lack of correlation or even an inverse correlation between an apparently favourable IFNL4 genotype and response to NS5A-based direct-acting antiviral therapy in patients with genotype 1b HCV infection.
Reference: Hepatology. 2016;63(1):63-73 Abstract

Predictors of hepatitis B e antigennegative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood
Authors: Wu J-F et al. Summary: In this study, 434 hepatitis B e antigen (HBeAg)-positive chronic HBV-infected Taiwanese patients were followed from childhood (median age 7.22 years) through to adulthood, in an attempt to predict the risk of developing HBeAg-negative hepatitis in later life. Spontaneous HBeAg seroconversion occurred in 359 subjects at a median age of 13.93 years; the remaining 75 patients developed HBeAg seroconversion after antiviral therapy. Follow-up continued for a median 14.40 years after HBeAg seroconversion. The HBV basal core promoter and precore/core gene sequences were also evaluated in subjects with and without HBeAg-negative hepatitis. The overall annual incidence of HBeAg-negative hepatitis was 0.37% (95% CI, 0.35 to 0.39) in spontaneous HBeAg seroconverters. The overall annual incidence of HBeAg-negative hepatitis increased to 2.64% in lamivudine-treated subjects but did not increase in those treated with interferon-α (0.58%). In multivariate analysis, male gender (hazard ratio [HR] 3.15), HBV genotype C (HR 4.40), HBeAg seroconversion after 18 years of age (HR 2.46) and lamivudine therapy prior to HBeAg seroconversion (HR 1.42) were predictors of HBeAg-negative hepatitis in HBeAg seroconverters (p<0.05). A 1762 T/G 1764 A, C 2063 A, and A 2131 C HBV gene mutations were more prevalent in HBeAg-negative subjects than in those without HBeAg-negative hepatitis.
Comment: This long-term, large-scale cohort study from Taiwan followed patients from childhood to adulthood in order to investigate the impact of possible risk factors for the development of HBeAgnegative chronic hepatitis following HBeAg seroconversion. Male gender, genotype C (rather than genotype B) infection, HBV seroconversion after 18 years of age and prior lamivudine therapy (rather than spontaneous HBeAg seroconversion or that following interferon-alpha treatment) were found to be significant predictors of HBeAg-negative chronic hepatitis. Before the onset of HBeAgnegative chronic hepatitis, such patients carried significantly more basal core promoter and precore/core gene mutations after spontaneous HBeAg seroconversion than subjects who did not develop HBeAg-negative chronic hepatitis. Based on these findings, interferon-based therapy for appropriate patients in childhood, especially boys with genotype C infection, with the aim of promoting HBeAg seroconversion prior to adulthood, might be expected to reduce the likelihood of HBeAg-negative chronic hepatitis in later life.
Reference: Hepatology. 2016;63(1):74-82 Abstract
Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B Authors: Yoshio S et al. Summary: These researchers explored the roles of the enzyme indoleamine-2,3-dioxygenase (IDO) in HBV clearance in an infected cohort of patients (acute hepatitis, n=25; chronic hepatitis, n=14; hepatic flare, n=14). IDO activity was also assessed in 14 healthy volunteers. The researchers used a culture model consisting of human natural killer cells, plasmacytoid dendritic cells, and HBV-transfected Huh7 cells. Acute hepatitis was associated with a robust activation of IDO and an inverse correlation of alanine aminotransferase at the peak, whereas this did not occur with hepatic flare. In acute hepatitis patients who eventually cleared HBV, IDO activity, chemokine (C-X-C motif) ligand 9 (CXCL9), CXCL10 and CXCL11 increased at the peak of alanine aminotransferase, whereas in patients with hepatic flare, IDO activity remained at lower levels, regardless of the surge of CXCL9, CXCL10, and CXCL11 at the alanine aminotransferase peak. IDO activity and HBV suppression in Huh7 cells was enhanced by co-existing natural killer cells and plasmacytoid dendritic cells producing interferon-γ and interferon-α. This suppressive effect of IDO on HBV was abolished in IDO-knockout cells and recovered after IDO was reintroduced.
Comment: Indoleamine-2,3-dioxygenase (IDO) is an enzyme, inducible by inflammatory mediators including interferon-gamma (IFN-g) and interferon-alpha (IFN-α), that catalyses tryptophan to kynurenine. Reported effects include the promotion of immune tolerance via T cell inhibition, while suppression of HBV replication in transfected HepG2 cells has also been documented. The role of IDO in patients with acute HBV infection is yet to be determined. This study included both a longitudinal clinical assessment and an in vitro culture model comprising HBV-positive Huh7 cells, natural killer (NK) cells and plasmacytoid dendritic cells (pDCs) and found that IDO activation in the early phase of acute HBV infection is important for viral clearance, likely via a noncytopathic effect. Synergistic production of IFN-g and IFN-α by NK cells and pDCs enhanced IDO activity and its suppressive effect on HBV replication in vitro. The findings add to current understanding of mechanisms promoting viral clearance in acute HBV infection. : Hepatology. 2016; 63(1):83-94 Abstract Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin Authors: Younossi ZM et al. Summary: These researchers assessed changes in the serum lipid and distal (post-squalene) cholesterol biosynthesis metabolite profile of 50 patients infected with HCV genotype (GT) 2 and 77 patients with HCV GT3, all of whom were treated with sofosbuvir and ribavirin. Serum samples obtained at baseline, after 12 weeks of treatment and again at 4 weeks post-treatment were analysed for apolipoproteins B and E (apoB/E), total cholesterol, HDL, LDL, and 11 post-squalene sterol metabolites. Half of the patients (50%) had cirrhosis and 42% experienced a virological relapse. At baseline, serum levels of lipids, apoB/E, 7-dehydrocholesterol, desmosterol and lathosterol were lower in the GT3 cohort than in the GT2 cohort (p<0.006). Baseline lathosterol was lower in relapsers with cirrhosis compared to cirrhotics who achieved a sustained virological response (SVR) (p=0.003). From baseline to treatment week 12, serum lipids, apoB/E, and key sterol pathway metabolites (7-dehydrocholesterol, desmosterol, lathosterol, lanosterol) increased in GT3. In contrast, in GT2 patients, apoB/E and dihydrolanosterol decreased with viral suppression (p<0.025). At 4 weeks post-treatment, cirrhotic SVR patients had substantially greater increases in apoB and total sterols compared to cirrhotic relapsers, regardless of HCV genotype. In analyses adjusted for genotype and gender, baseline lathosterol was independently associated with virological response (p=0.04).
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